The beneficial effect of clopidogrel over aspirin monotherapy following dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) is consistent regardless of clinical risk or relative ischemic and bleeding risks, according to a new post hoc analysis of the HOST-EXAM trial.